Live Breaking News & Updates on Ikarian Capital

Stay updated with breaking news from Ikarian capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cybin's (CYBN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Cybin (NYSE:CYBN – Free Report) in a research report report published on Thursday, Benzinga reports. The brokerage currently has a $5.00 price objective on the stock. HC Wainwright also issued estimates for Cybin’s FY2029 earnings at $0.26 EPS. Cybin Stock Down 0.6 % NYSE:CYBN opened at […] ....

Cybin Inc , Ikarian Capital , Investment Company Inc , Free Report , Stock Down , Get Free Report , Cybin Daily ,

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $84,320.00 in Stock

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) insider Hunter Gillies sold 4,000 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $21.08, for a total value of $84,320.00. Following the sale, the insider now owns 5,602 shares in the company, valued at approximately […] ....

United States , Hunter Gillies , Jefferies Financial Group , Aerovate Therapeutics Company Profile , Wells Fargo Company , Alps Advisors Inc , Securities Exchange Commission , Aerovate Therapeutics Inc , Vanguard Group Inc , Eventide Asset Management , Ikarian Capital , Aerovate Therapeutics , Get Free Report , Exchange Commission , Therapeutics Trading Down , Financial Group , Wells Fargo , Asset Management , Point Capital , Alps Advisors , Aerovate Therapeutics Daily ,

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Timothy P. Noyes Sells 10,000 Shares

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) CEO Timothy P. Noyes sold 10,000 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $21.58, for a total value of $215,800.00. The sale was disclosed in a document filed with the SEC, which can be […] ....

United States , Switzerland General , Timothyp Noyes , Silverarc Capital Management , Wells Fargo Company , Alps Advisors Inc , Eventide Asset Management , Aerovate Therapeutics Inc , Jefferies Financial Group , Ikarian Capital , Swiss National Bank , Aerovate Therapeutics , Get Free Report , Financial Group , Wells Fargo , Asset Management , National Bank , Capital Management , Aerovate Therapeutics Daily ,

Wedbush Reiterates "Outperform" Rating for Aerovate Therapeutics (NASDAQ:AVTE)

Wedbush reaffirmed their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research note released on Tuesday, Benzinga reports. They currently have a $41.00 price target on the stock. Wedbush also issued estimates for Aerovate Therapeutics’ Q2 2024 earnings at ($0.71) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings […] ....

Switzerland General , United States , Marinus Verwijs , Timothyp Noyes , Ikarian Capital , Alps Advisors Inc , Jefferies Financial Group , Aerovate Therapeutics Inc , Wells Fargo Company , Aerovate Therapeutics Company Profile , Vanguard Group Inc , Silverarc Capital Management , Swiss National Bank , Securities Exchange Commission , Aerovate Therapeutics , Free Report , Financial Group , Get Free Report , Exchange Commission , National Bank , Capital Management , Vanguard Group , Aerovate Therapeutics Daily ,

Stifel Nicolaus Reaffirms Buy Rating for Nyxoah (NASDAQ:NYXH)

Stifel Nicolaus restated their buy rating on shares of Nyxoah (NASDAQ:NYXH – Free Report) in a report published on Wednesday morning, Benzinga reports. The firm currently has a $27.00 target price on the stock. Several other analysts also recently weighed in on the company. HC Wainwright restated a buy rating and issued a $22.00 price […] ....

Stifel Nicolaus , Piper Sandler , Ikarian Capital , Cantor Fitzgerald , Free Report , Moderate Buy , Get Free Report , Nyxoah Daily ,